| Kim, Tae Won |
NCT06338995: A Study of Lebrikizumab (LY3650150) in Adult Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP) |
|
|
| Recruiting | 3 | 510 | Europe, Canada, Japan, US, RoW | LY3650150, Placebo, Standard therapy for INCS | Eli Lilly and Company | Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) | 10/26 | 02/27 | | |
| Recruiting | 3 | 1200 | Europe, Canada, Japan, US, RoW | Remternetug, LY3372993, Placebo | Eli Lilly and Company | Alzheimer's Disease | 04/29 | 10/30 | | |
| Recruiting | 3 | 778 | Europe, Canada, Japan, US, RoW | Mirikizumab, LY3074828 | Eli Lilly and Company | Crohn's Disease | 11/24 | 12/26 | | |
NCT06598943: A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis |
|
|
| Recruiting | 2 | 140 | Europe, Japan, US, RoW | Eltrekibart, LY3041658, Mirikizumab, LY3074828, Placebo | Eli Lilly and Company | Ulcerative Colitis, Ulcerative Colitis Chronic | 12/27 | 09/28 | | |
| Recruiting | 2 | 180 | Europe, Japan, US, RoW | Epcoritamab, GEN3013, DuoBody®-CD3×CD20, EPKINLY™, Lenalidomide, Revlimid® | Genmab, AbbVie | Diffuse Large B-Cell Lymphoma | 01/26 | 07/27 | | |
| Recruiting | 2 | 250 | Europe, Canada, US, RoW | Plixorafenib, FORE8394, PLX8394, Cobicistat, TYBOST(R) | Fore Biotherapeutics, Fore Biotherapeutics | Cancer Harboring BRAF Alterations | 06/25 | 08/26 | | |
| Active, not recruiting | 2 | 154 | Europe, Canada, Japan, US, RoW | Dostarlimab, JEMPERLI, dostarlimab-gxly, TSR-042, GSK4057190A | GlaxoSmithKline, GlaxoSmithKline Research & Development Ltd | Neoplasms, Rectal | 11/26 | 10/29 | | |
| Active, not recruiting | 1/2 | 323 | US, RoW | FLX475, pembrolizumab (KEYTRUDA®) | RAPT Therapeutics, Inc., Merck Sharp & Dohme LLC | Advanced Cancer | 09/24 | 01/25 | | |
NCT04903873: A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 110 | US, RoW | EU101 | Eutilex | Solid Tumor, Renal Cell Cancer Metastatic, Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Prostate Cancer | 09/25 | 12/25 | | |
METex14, NCT04868877 / 2021-000203-20: Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination |
|
|
| Recruiting | 1/2 | 576 | Europe, US, RoW | MCLA-129, bispecific, Osimertinib, Tagrisso, Chemotherapy | Merus N.V. | Non-Small Cell Lung Cancer Metastatic, Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer | 03/26 | 03/27 | | |
NCT05394831: A Phase 1/2 Study to Evaluate the Safety, Tolerability and PK of JIN-A02 in Patients With EGFR Mutant Advanced NSCLC |
|
|
| Recruiting | 1/2 | 150 | US, RoW | JIN-A02 | J Ints Bio | EGFR Mutant Advanced Non-small Cell Lung Cancer | 07/24 | 11/25 | | |
| Recruiting | 1 | 180 | Europe, US, RoW | IDE397, Docetaxel, Paclitaxel, Sacituzumab govitecan | IDEAYA Biosciences | Solid Tumor | 12/26 | 03/27 | | |
NCT03284502: HM95573 in Combination With Either Cobimetinib or Cetuximab in Patients With Locally Advanced or Metastatic Solid Tumors |
|
|
| Active, not recruiting | 1 | 148 | RoW | HM95573, cobimetinib, HM95573, cetuximab | Hanmi Pharmaceutical Company Limited | Locally Advanced Solid Tumor, Metastatic Solid Tumor | 09/24 | 12/24 | | |
NCT05159440: First in Human Study of TORL-2-307-MAB in Participants With Advanced Cancer |
|
|
| Active, not recruiting | 1 | 70 | US, RoW | TORL-2-307-MAB | TORL Biotherapeutics, LLC, Translational Research in Oncology | Advanced Solid Tumor, Gastric Cancer, Pancreas Cancer, Gastroesophageal Junction Adenocarcinoma | 12/24 | 12/25 | | |
NCT05156866: First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer |
|
|
| Recruiting | 1 | 70 | US, RoW | TORL-2-307-ADC | TORL Biotherapeutics, LLC, Translational Research in Oncology | Advanced Solid Tumor, Gastric Cancer, Pancreas Cancer, Gastroesophageal Junction Adenocarcinoma | 01/25 | 01/26 | | |
| Recruiting | 1 | 198 | Europe, US, RoW | ELVN-002, Fam-Trastuzumab Deruxtecan-Nxki, Enhertu, T-DXd, Trastuzumab emtansine, Kadcyla, T-DM1 | Enliven Therapeutics | HER2 Mutant Non-small Cell Lung Cancer, HER2-positive Metastatic Breast Cancer, HER2 Gene Mutation, HER2 Amplification | 07/26 | 07/26 | | |
| Not yet recruiting | N/A | 103 | RoW | Daclatasvir and Asunaprevir, Daclatasvir and Asunaprevir combined treatment for 24 weeks | Sang Gyune Kim, Seoul National University Boramae Hospital, Severance Hospital, Inha University Hospital, Korea University, Gachon University Gil Medical Center, Hanyang University Seoul Hospital, Ewha Womans University Mokdong Hospital, Bristol-Myers Squibb | Chronic Hepatitis C | 12/18 | 12/22 | | |
OBE-KMT22-01, NCT06250608: Evaluation of rSO2 Between Frontal Lesion Area and Normal Area of Brain by NIRSITX Using NIRS in Acute Ischemic Stroke Patients. |
|
|
| Recruiting | N/A | 35 | RoW | Pulse oximeter, NIRSITX | OBELAB, Inc., Helptrial Inc. | Acute Ischemic Stroke Patients | 12/25 | 12/25 | | |
ASSIST, NCT05529459: Anatomic Versus Physiologic Guidance for Complete Revascularization With DES Eluting in Patients With CAD |
|
|
| Recruiting | N/A | 2400 | RoW | Percutaneous Coronary Intervention | Seung-Whan Lee, M.D., Ph.D., Biotronik Korea Co., Ltd | Coronary Disease | 12/26 | 07/30 | | |
PROVE-DM, NCT05579626: Comparison of Low-Intensity Statin Plus Ezetimibe Versus High-Intensity Statin Therapy on Risk of New-Onset Diabetes Mellitus |
|
|
| Recruiting | N/A | 4000 | RoW | high-intensity statin arm, low-intensity statin plus ezetimibe | Seung-Whan Lee, M.D., Ph.D., Yuhan Corporation | Pre Diabetes, ASCVD | 12/27 | 12/27 | | |
NCT05467930: CU-COMMITS: COVID-19 Care in Black and Latino Communities and Households. Clinical and Molecular Outcomes of SARS-CoV-2 |
|
|
| Recruiting | N/A | 1000 | US | Survey, Medical History Review, Sample Collection | Columbia University, Gilead Sciences | COVID-19, SARS CoV 2 Infection | 05/25 | 05/26 | | |
| Sarin, Shiv K |
| Active, not recruiting | 3 | 871 | Europe, Canada, Japan, US, RoW | Bepirovirsen, Placebo | GlaxoSmithKline, GlaxoSmithKline Research & Development Limited | Chronic Hepatitis B, Hepatitis B, Chronic | 11/25 | 05/26 | | |
| Active, not recruiting | 2 | 271 | Europe, Canada, Japan, US, RoW | GSK4532990, Placebo | GlaxoSmithKline, GlaxoSmithKline Research & Development Limited | Nonalcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver Disease | 12/25 | 03/26 | | |
| Zhu, Haidong |
NCT04520906: To Evaluate the Safety and Efficacy of Microwave Ablation Therapy in Patients With Primary Liver Cancer |
|
|
| Recruiting | N/A | 139 | RoW | microwave ablation | Suzhou Hengruihongyuan Medical Technology Co. LTD | Hepatocellular Carcinoma | 01/23 | 12/23 | | |
| Teng, Gao-Jun |
NCT05631561: Endovascular Denervation for the Treatment of Type 2 Diabetes Mellitus |
|
|
| Active, not recruiting | N/A | 30 | RoW | Endovascular denervation System (Generator and Catheter ) | Shanghai Golden Leaf MedTec Co. Ltd | Type 2 Diabetes Mellitus (T2DM) | 04/24 | 02/25 | | |
NCT05956860: Radial Access for Abdominopelvic Vascular Intervention |
|
|
| Recruiting | N/A | 1143 | RoW | abdominopelvic vascular intervention through the radial artery access | Zhongda Hospital, Terumo Medical Corporation | Vascular Access Device Complications | 12/24 | 12/25 | | |
| Li, Ying |
STRATEGY, NCT05310968: Study on Tirofiban With Aspirin in the Treatment of Acute Penetrating Artery Territory Infarction |
|
|
| Recruiting | 4 | 970 | RoW | Tirofiban hydrochloride sodium chloride injection, Tirofiban hydrochloride sodium chloride injection placebo, Aspirin | Beijing Tiantan Hospital, GrandPharma (China) Co., Ltd. | Branch Atheromatous Disease | 06/24 | 09/24 | | |
NCT04624854: Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD) |
|
|
| Active, not recruiting | 4 | 8250 | RoW | Clopidogrel and Aspirin dual-antiplatelet therapy, Aspirin monotherapy | Harbin Medical University, Chinese Society of Cardiology, Lepu Medical Technology (Beijing) Co., Ltd. | Coronary Artery Disease, Myocardial Ischemia, Acute Coronary Syndrome, Heart Diseases, Syndrome Heart Disease, Cardiovascular Diseases, Arteriosclerosis, Arterial Occlusive Diseases, Coronary Disease, Vascular Diseases | 04/25 | 04/25 | | |
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) |
|
|
| Recruiting | 3 | 12500 | Europe, Canada, Japan, US, RoW | Lepodisiran Sodium, LY3819469, Placebo | Eli Lilly and Company | Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a) | 03/29 | 03/29 | | |
NCT06775860: ICP-332 in Subjects with Moderate to Severe Atopic Dermatitis |
|
|
| Recruiting | 3 | 552 | RoW | ICP-332 Tablets, ICP-332 Placebo Tablets | Beijing InnoCare Pharma Tech Co., Ltd. | Atopic Dermatitis | 11/26 | 12/26 | | |
NCT06631170: Efficacy and Safety of Roflumilast Cream in Subjects with Atopic Dermatitis |
|
|
| Recruiting | 3 | 351 | RoW | Roflumilast Cream 0.15%, Vehicle cream | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Atopic Dermatitis (AD) | 08/25 | 08/25 | | |
| Recruiting | 2 | 120 | RoW | TQH3906 capsules, Placebo of TQH3906 capsules | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Plaque Psoriasis | 01/25 | 09/25 | | |
| Recruiting | 1 | 48 | RoW | TQB2928 Injection + Azacitidine for injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Acute Myeloid Leukemia, Myelodysplastic Syndromes | 05/25 | 05/25 | | |
| Active, not recruiting | N/A | 7656 | RoW | JT001, DeuremidevirHydrobromideTablets | Shanghai Vinnerna Biosciences Co., Ltd. | COVID-19 | 11/24 | 12/24 | | |
| Qiu, Haibo |
NCT05000671: A Study to Evaluate the Safety and Effect of STC314 Injection Continuous Infusion in Subjects With Acute Respiratory Distress Syndrome |
|
|
| Recruiting | 1 | 16 | RoW | STC314 injection or Placebo(rate=58.3 mg/hr), STC314 injection or Placebo(rate=87.5 mg/hr) | Grand Medical Pty Ltd., Grand Pharmaceutical (China) Co., Ltd. | Acute Respiratory Distress Syndrome | 12/22 | 12/22 | | |
NCT04936178: A Study of NB003 in Patients With Advanced Malignancies |
|
|
| Recruiting | 1 | 258 | Europe, US, RoW | NB003 tablets | Ningbo Newbay Technology Development Co., Ltd | Advanced Solid Tumor | 07/25 | 12/25 | | |
| Liu, Ling |
NCT04845399: Phase III Expansion Trial for Determining the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A |
|
|
| Completed | 3 | 101 | RoW | Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection | Zhengzhou Gensciences Inc, Jiangsu Gensciences lnc. | Hemophilia A | 06/21 | 06/21 | | |
SPH3127-301, NCT05359068: Study to Evaluate the Efficacy and Safety of SPH3127 In Patients With Mild-moderate Essential Hypertension |
|
|
| Completed | 3 | 957 | RoW | SPH3127 tablet, Valsartan | Shanghai Pharmaceuticals Holding Co., Ltd | Essential Hypertension | 12/23 | 12/23 | | |
NCT06038916: To Evaluate the Safety and Initial Efficacy of STSA-1002 Injection in Patients with Acute Respiratory Distress Syndrome |
|
|
| Recruiting | 1/2 | 60 | RoW | STSA-1002 Injection Placebo, STSA-1002 Injection | Staidson (Beijing) Biopharmaceuticals Co., Ltd | Acute Respiratory Distress Syndrome | 08/25 | 09/26 | | |
NCT06529445: Food Effect and Relative Bioavailability Study of VC004 Capsules in Healthy Adult Subjects |
|
|
| Completed | 1 | 84 | RoW | High Dose VC004 Capsules, Median Dose VC004 Capsules, Low Dose VC004 Capsules | Jiangsu vcare pharmaceutical technology co., LTD | Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene Fusion | 08/24 | 08/24 | | |
NCT06619951: A Clinical Trial to Evaluate the Effects of Itraconazole or Rifampicin on the Pharmacokinetics of VC004 Capsules in Healthy Adult Subjects |
|
|
| Completed | 1 | 56 | RoW | VC004 and Itraconazole, VC004 and rifampicin | Jiangsu vcare pharmaceutical technology co., LTD | Locally Advanced or Metastatic Solid Tumor | 10/24 | 10/24 | | |
NCT05219643: Effect of Nava on Weaning Outcome in Patients With Mechanical Ventilation |
|
|
| Recruiting | N/A | 130 | RoW | NAVA, PSV | Southeast University, China, First Affiliated Hospital of Wannan Medical College | ARDS | 12/24 | 02/25 | | |
| Li, Jia |
ALTN-AK105-III-02, NCT04344158: A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC) |
|
|
| Active, not recruiting | 3 | 648 | RoW | AK105 Injection, Anlotinib Hydrochloride Capsules, Sorafenib Tosylate Tablets | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Hepatocellular Carcinoma (HCC) | 12/26 | 12/26 | | |
NATiV3, NCT04849728: A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( ) |
|
|
| Recruiting | 3 | 1000 | Europe, Canada, US, RoW | IVA337, Lanifibranor, Placebo | Inventiva Pharma | NASH - Nonalcoholic Steatohepatitis | 09/25 | 09/26 | | |
NCT06412471: A Phase II Study of SSGJ-707 Combination Therapy in Advanced NSCLC Patients |
|
|
| Recruiting | 2 | 235 | RoW | SSGJ-707, carboplatin, Pemetrexed, paclitaxel, PD-1/L1, Paclitaxel-albumin | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | First-line Advanced NSCLC Patients | 07/25 | 08/25 | | |
NCT05552781: H002 in Patients With EGFR Mutation Locally Advanced or Metastatic NSCLC |
|
|
| Recruiting | 1/2 | 76 | RoW | H002 capsule, H002 | RedCloud Bio, R&G Pharma Studies Co.,Ltd. | Non-small Cell Lung Cancer | 02/25 | 02/25 | | |
| Wang, Yu |
RC48-C012, NCT04400695: A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2 |
|
|
| Recruiting | 3 | 366 | RoW | RC48-ADC, RC48, Paclitaxel Injection, Taxol, Docetaxel Injection, Taxotere, Vinorelbine Tartrate Injection, Navelbine, Capecitabine Tablets, Xeloda | RemeGen Co., Ltd. | Breast Cancer | 06/24 | 12/24 | | |
| Active, not recruiting | 3 | 291 | Europe, Canada, Japan, US, RoW | Selpercatinib, LY3527723, LOXO-292, Cabozantinib, Vandetanib | Loxo Oncology, Inc., Eli Lilly and Company | Medullary Thyroid Cancer | 05/23 | 02/26 | | |
NCT04787328: A Study of HA121-28 Tablets in Patients With Medullary Thyroid Carcinoma (MTC) |
|
|
| Recruiting | 2 | 30 | RoW | HA121-28 tablets | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Medullary Thyroid Carcinoma | 03/23 | 03/25 | | |
NCT06569524: Efficacy and Safety of Recombinant Human FGF21-Fc Fusion Protein for Injection (TQA2225/AP025) in Adult Subjects With Non-alcoholic Steatohepatitis (NASH) |
|
|
| Recruiting | 2 | 120 | RoW | TQA2225/AP025 or TQA2225/AP025 Placebo 25mg, TQA2225/AP025 or TQA2225/AP025 Placebo 50mg | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Non-alcoholic Steatohepatitis | 12/26 | 12/27 | | |
NCT04583020: Neoadjuvant PD-1 in Newly Diagnosed Glioblastoma |
|
|
| Recruiting | 2 | 42 | RoW | Camrelizumab, radiation, Temozolomide, TMZ | Peking Union Medical College Hospital, Jiangsu HengRui Medicine Co., Ltd. | Glioblastoma | 12/23 | 12/23 | | |
NCT05123586: A IMMA Master Protocol: A Study of LY3361237 in Participants With at Least Moderately Active Systemic Lupus Erythematosus |
|
|
| Terminated | 2 | 85 | Europe, US, RoW | LY3361237, Placebo | Eli Lilly and Company | Systemic Lupus Erythematosus | 12/23 | 12/23 | | |
NCT06109818: Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ICP-488 in Patients With Moderate to Severe Plaque Psoriasis |
|
|
| Recruiting | 2 | 129 | RoW | ICP-488 Tablets, ICP-488 Placebo | Beijing InnoCare Pharma Tech Co., Ltd. | Moderate to Severe Plaque Psoriasis | 10/24 | 11/24 | | |
NCT06077331: A Study to Evaluate Efficacy and Safety of HS-10374 for Moderate to Severe Plaque Psoriasis |
|
|
| Recruiting | 2 | 120 | RoW | HS-10374 tablets 1mg, HS-10374 tablets 5mg, HS-10374-matched placebo tablets | Hansoh BioMedical R&D Company | Psoriasis | 07/24 | 08/24 | | |
NCT05422066: Selinexor Plus R-CHOP in High-risk GCB-subtype Diffuse Large B-Cell Lymphoma |
|
|
| Recruiting | 2 | 50 | RoW | Selinexor, ATG-010, Xpovio, Rituximab, RiTUXimab Injection, Cyclophosphamide, Cyclophosphamide Injection, Doxorubicin, Doxorubicin Hydrochloride, Vincristine, Vincristine Injection, Prednisone, Prednisone Oral Product | Li Zhiming, Antengene Corporation | DLBCL Germinal Center B-Cell Type | 07/25 | 12/25 | | |
|
NCT05102292: The Efficacy and Safety of HLX208 in Advanced Anaplastic Thyroid Cancer (ATC) With BRAF V600 Mutation |
|
|
| Active, not recruiting | 1/2 | 25 | RoW | HLX208, BRAF V600E inhibitor | Shanghai Henlius Biotech | Anaplastic Thyroid Cancer, ATC | 06/24 | 12/24 | | |
| Recruiting | 1 | 117 | RoW | SG2918 | Hangzhou Sumgen Biotech Co., Ltd. | Advanced Malignant Tumors | 12/25 | 12/26 | | |
| Recruiting | 1 | 125 | Europe, Canada, US | Cohort A1 & A2, KTX-1001, Dexamethasone, Cohort C1 & C2, Carfilzomib, Cohort D, Pomalidomide | K36 Therapeutics, Inc. | Multiple Myeloma, Myeloma, Myeloma Multiple | 12/25 | 06/26 | | |
| Recruiting | N/A | 100 | RoW | Automated peritoneal dialysis, Intermittent hemodialysis | Limeng Chen, First Hospital of China Medical University, First Affiliated Hospital Xi'an Jiaotong University, Beijing Anzhen Hospital, Xiangya Hospital of Central South University, Baxter Healthcare Corporation | Acute Kidney Injury | 12/22 | 12/22 | | |
NCT04995159: Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVasâ„¢ BRS System |
|
|
| Not yet recruiting | N/A | 2150 | RoW | Single anti-platelet therapy, SAPT strategy, Dual anti-platelet therapy, DAPT strategy | Lepu Medical Technology (Beijing) Co., Ltd. | Coronary Heart Disease | 01/26 | 01/28 | | |
| Xie, Qing |
| Active, not recruiting | 4 | 640 | RoW | Tenofovir Amibufenamide（TMF）, HS-10234 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Hepatitis B, Chronic | 06/24 | 09/29 | | |
| Active, not recruiting | 3 | 871 | Europe, Canada, Japan, US, RoW | Bepirovirsen, Placebo | GlaxoSmithKline, GlaxoSmithKline Research & Development Limited | Chronic Hepatitis B, Hepatitis B, Chronic | 11/25 | 05/26 | | |
NCT04147208: Evaluate the Safety, Tolerability, and Antiviral Activity of GLS4 With Ritonavir in Patients With Chronic HBV Infection |
|
|
| Completed | 2 | 250 | RoW | GLS4, Morphothiadine Mesilate Capsules, RTV, Ritonavir tablet, ETV, Entecavir table | Sunshine Lake Pharma Co., Ltd. | Chronic HBV Infection | 06/22 | 09/23 | | |
NCT06042764: SA55 Injection Phase II Study in the Treatment of Mild/Moderate COVID-19 Patients |
|
|
| Recruiting | 2 | 150 | RoW | SA55 Injection | Sinovac Life Sciences Co., Ltd. | Infection of Upper Respiratory Tract Caused by 2019-nCoV | 03/24 | 08/24 | | |
TQA3605-II-01, NCT06644417: Clinical Study of TQA3605 Tablets Combined With Nucleoside (Acid) Analogs (NAs) Drugs Compared With NAs Drugs in the Treatment of Chronic Hepatitis B Virus (HBV) Infection |
|
|
| Recruiting | 2 | 120 | RoW | TQA3605 tablets plus NAs, TQA3605 Placebo plus NAs | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | HBV Infection With LLV | 04/26 | 08/26 | | |
| Recruiting | 2 | 450 | Europe, Canada, Japan, US, RoW | Bepirovirsen, Placebo | GlaxoSmithKline, GlaxoSmithKline Research & Development Limited | Hepatitis B | 02/29 | 02/29 | | |
Promote, NCT05797714: The Effectiveness and Safety of TMF in the Treatment of Chronic Hepatitis B Patients With Normal ALT. |
|
|
| Active, not recruiting | N/A | 200 | RoW | Tenofovir Amibufenamide（TMF）, HengMu | Ruijin Hospital, Jiangsu Hansoh Pharmaceutical Co., Ltd. | HBV Infection, Chronic Hepatitis b | 06/24 | 04/26 | | |
C-DIAMOND, NCT04952207: Effectiveness and Safety of Direct-Acting Antiviral Agents for the Treatment of Chronic Hepatitis C |
|
|
| Recruiting | N/A | 300 | RoW | Direct-acting antiviral agents, daclatasvir, asunaprevir, ombitasvir, paritaprevir, dasabuvir, sofosbuvir, velpatasvir, ledipasvir, elbasvir, grazoprevir, danoprevir, glecaprevir, pibrentasvir, voxilaprevir | Qing XIe, Gilead Sciences, Tigermed Consulting Co., Ltd | Hepatitis C, Chronic | 07/21 | 08/21 | | |
| Teng, Gaojun |
AK104-308, NCT06371157: A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma |
|
|
| Not yet recruiting | 3 | 469 | RoW | AK104, Lenvatinib, TACE, Placebo for AK104, Placebo for Lenvatinib | Akeso | Hepatocellular Carcinoma | 10/25 | 05/26 | | |
| Active, not recruiting | 3 | 92 | RoW | TheraSphere™ Yttrium-90 Glass Microspheres, conventional Transarterial Chemoembolization(cTACE) | Boston Scientific Corporation | Inoperable Hepatocellular Carcinoma | 02/26 | 10/26 | | |
NCT06310590: Safety and Efficacy of NRT6003 in Patients With Unresectable Hepatocellular Carcinoma |
|
|
| Recruiting | 1 | 40 | RoW | NRT6003 Injection, Yttrium-90 carbon microspheres | Chengdu New Radiomedicine Technology Co. LTD. | Unresectable Hepatocellular Carcinoma | 10/25 | 10/25 | | |
NCT04520906: To Evaluate the Safety and Efficacy of Microwave Ablation Therapy in Patients With Primary Liver Cancer |
|
|
| Recruiting | N/A | 139 | RoW | microwave ablation | Suzhou Hengruihongyuan Medical Technology Co. LTD | Hepatocellular Carcinoma | 01/23 | 12/23 | | |
NCT05956860: Radial Access for Abdominopelvic Vascular Intervention |
|
|
| Recruiting | N/A | 1143 | RoW | abdominopelvic vascular intervention through the radial artery access | Zhongda Hospital, Terumo Medical Corporation | Vascular Access Device Complications | 12/24 | 12/25 | | |
| Yang, Yi |
NCT04739592: A Study of Alendronate Sodium Vitamin D3 Tablets on Knee Osteoarthritis |
|
|
| Recruiting | 4 | 60 | RoW | alendronate sodium vitamin D3 tablets, Placebo | Peking Union Medical College Hospital, CSPC Ouyi Pharmaceutical Co., Ltd. | Knee Osteoarthritis | 07/23 | 07/24 | | |
| Completed | 3 | 1412 | RoW | Injection of recombinant human tissue plasminogen kinase derivatives, Reteplase, brand name: Ruitongli, r-PA, Recombinant human tissue plasminogen activator, Alteplase, brand name: Actilyse, rt-PA | Angde Biotech Pharmaceutical Co., Ltd., Beijing Tiantan Hospital | Acute Ischemic Stroke | 06/23 | 06/23 | | |
NCT06338995: A Study of Lebrikizumab (LY3650150) in Adult Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP) |
|
|
| Recruiting | 3 | 510 | Europe, Canada, Japan, US, RoW | LY3650150, Placebo, Standard therapy for INCS | Eli Lilly and Company | Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) | 10/26 | 02/27 | | |
SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer |
|
|
| Recruiting | 3 | 1016 | Europe, Canada, Japan, US, RoW | LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed | Eli Lilly and Company, Loxo Oncology, Inc. | Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis | 10/26 | 10/29 | | |
| Recruiting | 3 | 170 | Europe, Canada, Japan, US, RoW | Selpercatinib, LY3527723, LOXO-292, Placebo | Loxo Oncology, Inc., Eli Lilly and Company | Carcinoma, Non-Small-Cell Lung | 05/27 | 08/32 | | |
NCT04898322: SY-005 （Recombinant Human Annexin A5）in Patients With Sepsis |
|
|
| Recruiting | 2a | 96 | RoW | SY-005, Placebo | Suzhou Yabao Pharmaceutical R&D Co., Ltd. | Sepsis | 07/23 | 07/23 | | |
NCT05865496: A Study to Evaluate 611 in Patients With Chronic Rhinosinusitis With Nasal Polyps |
|
|
| Active, not recruiting | 2 | 90 | RoW | 611, Placebo | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Sinusitis, Nasal Polyps, Polyps | 05/24 | 07/24 | | |
NCT05686642: Efficacy and Safety of LT3001 on Treating the Acute Ischemic Stroke |
|
|
| Recruiting | 2 | 300 | RoW | LT3001 Drug:high dose, Placebo, LT3001 Drug:low dose | Shanghai Pharmaceuticals Holding Co., Ltd | Acute Ischemic Stroke | 04/25 | 07/25 | | |
NCT06089278: A Clinical Study of TQH2722 Injection in the Treatment of Chronic Sinusitis With or Without Nasal Polyps. |
|
|
| Recruiting | 2 | 160 | RoW | 300mg of TQH2722 injection, 600mg of TQH2722 injection, TQH2722 injection matching placebo | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Sinusitis | 05/25 | 05/25 | | |
NCT06038916: To Evaluate the Safety and Initial Efficacy of STSA-1002 Injection in Patients with Acute Respiratory Distress Syndrome |
|
|
| Recruiting | 1/2 | 60 | RoW | STSA-1002 Injection Placebo, STSA-1002 Injection | Staidson (Beijing) Biopharmaceuticals Co., Ltd | Acute Respiratory Distress Syndrome | 08/25 | 09/26 | | |
NCT04536337: A Study of ALG-000184 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single and Multiple Doses in Healthy Volunteers and CHB Subjects |
|
|
| Recruiting | 1 | 336 | Europe, RoW | ALG-000184, Placebo, Entecavir | Aligos Therapeutics | Chronic Hepatitis B | 11/23 | 06/24 | | |
| Not yet recruiting | N/A | 342 | RoW | Osimertinib, Alectinib, TORIPALIMAB INJECTION (JS001 ) combine with chemotherapy | Guangdong Association of Clinical Trials, Nanjing Geneseeq Technology Inc. | Non-Small Cell Lung Cancer | 01/29 | 01/32 | | |
| Ma, Genshan |
NCT04624854: Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD) |
|
|
| Active, not recruiting | 4 | 8250 | RoW | Clopidogrel and Aspirin dual-antiplatelet therapy, Aspirin monotherapy | Harbin Medical University, Chinese Society of Cardiology, Lepu Medical Technology (Beijing) Co., Ltd. | Coronary Artery Disease, Myocardial Ischemia, Acute Coronary Syndrome, Heart Diseases, Syndrome Heart Disease, Cardiovascular Diseases, Arteriosclerosis, Arterial Occlusive Diseases, Coronary Disease, Vascular Diseases | 04/25 | 04/25 | | |
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) |
|
|
| Recruiting | 3 | 12500 | Europe, Canada, Japan, US, RoW | Lepodisiran Sodium, LY3819469, Placebo | Eli Lilly and Company | Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a) | 03/29 | 03/29 | | |
| Recruiting | N/A | 4500 | RoW | | Harbin Medical University, Abbott | Acute Myocardial Infarction | 07/21 | 12/22 | | |
NCT04995159: Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVasâ„¢ BRS System |
|
|
| Not yet recruiting | N/A | 2150 | RoW | Single anti-platelet therapy, SAPT strategy, Dual anti-platelet therapy, DAPT strategy | Lepu Medical Technology (Beijing) Co., Ltd. | Coronary Heart Disease | 01/26 | 01/28 | | |
| Chen, LIjuan |
| Recruiting | 3 | 240 | RoW | Equecabtagene Autoleucel Injection, FUCASO, Daratumumab, Pomalidomide, Bortezomib, Dexamethasone | Nanjing IASO Biotechnology Co., Ltd. | Multiple Myeloma | 08/27 | 12/30 | | |
BENCH, NCT04939142: A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) |
|
|
| Active, not recruiting | 3 | 150 | RoW | SVd (Selinexor+Bortezomib+dexamethasone), Vd (Bortezomib+dexamethasone) | Antengene Corporation | Relapsed or Refractory Multiple Myeloma | 07/24 | 10/24 | | |
NCT04674514: APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS in Subjects With Relapsed or Refractory Multiple Myeloma |
|
|
| Recruiting | 1/2 | 48 | RoW | APG-2575, Rd, Lenalidomide +Dexamethasone | Ascentage Pharma Group Inc. | Multiple Myeloma | 01/24 | 05/24 | | |
FUMANBA-2, NCT05181501: A Study of Fully Human BCMA CAR-T (CT103A) in Patients With Newly Diagnosed High-risk Multiple Myeloma |
|
|
| Not yet recruiting | 1 | 20 | RoW | Fully human BCMA chimeric antigen receptor autologous T cell injection (CT103A), CT103A | Nanjing IASO Biotherapeutics Co.,Ltd | Multiple Myeloma | 04/24 | 04/39 | | |
NCT06472479: LCAR-M61S and LCAR-M61D in Treatment of Relapsed/Refractory Multiple Myeloma |
|
|
| Not yet recruiting | N/A | 66 | RoW | LCAR-M61S cells preparation, Cyclophosphamide, Fludarabine, LCAR-M61D cells preparation | The First Affiliated Hospital with Nanjing Medical University, Nanjing Legend Biotech Co. | Relapsed/Refractory Multiple Myeloma | 08/28 | 10/29 | | |
| Liu, Lei |
JADE, NCT06256588: A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma |
|
|
| Recruiting | 3 | 864 | Europe, Canada, Japan, US, RoW | Dostarlimab, Placebo | GlaxoSmithKline | Neoplasms, Head and Neck | 05/28 | 07/29 | | |
| Terminated | 3 | 166 | Europe, Canada, Japan, US, RoW | Xevinapant (Debio 1143), IMRT, Placebo | EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany | Head and Neck Cancer | 08/24 | 08/24 | | |
NCT06601335: A Phase 3 Study of AK112 Plus AK117 Versus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) |
|
|
| Recruiting | 3 | 510 | RoW | AK117 in combination with AK112, Placebo in combination with Pembrolizumab | Akeso | Head and Neck Squamous Cell Carcinoma | 01/27 | 10/27 | | |
NCT06378177: A Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC) |
|
|
| Recruiting | 2 | 64 | RoW | LVGN6051 Monoclonal Antibody Injection, LVGN6051, toripalimab Injection, Paclitaxel injection | Lyvgen Biopharma Holdings Limited | Head and Neck Squamous Cell Carcinoma | 10/27 | 10/27 | | |
NCT05102006: Phase Ib/II Clinical Study of LBL-007 in Treatment of Advanced Malignant Tumors |
|
|
| Recruiting | 1/2 | 200 | RoW | LBL-007 Injection, LBL-007, Toripalimab Injection | Nanjing Leads Biolabs Co.,Ltd | Advanced Solid Tumor | 06/25 | 08/25 | | |
| Recruiting | 1/2 | 374 | Europe, Canada, Japan, US, RoW | Dazostinag, TAK-676, Pembrolizumab, Platinum, 5-fluorouracil | Takeda, Takeda Development Center Americas, Inc. (TDC Americas) | Solid Neoplasms | 01/26 | 01/26 | | |
